PTC THERAPEUTICS INC (PTCT) Fundamental Analysis & Valuation

NASDAQ:PTCT • US69366J2006

Current stock price

71.63 USD
-1.94 (-2.64%)
Last:

This PTCT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. PTCT Profitability Analysis

1.1 Basic Checks

  • PTCT had positive earnings in the past year.
  • In the past year PTCT had a positive cash flow from operations.
  • In the past 5 years PTCT reported 4 times negative net income.
  • In the past 5 years PTCT reported 4 times negative operating cash flow.
PTCT Yearly Net Income VS EBIT VS OCF VS FCFPTCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M

1.2 Ratios

  • With an excellent Return On Assets value of 23.55%, PTCT belongs to the best of the industry, outperforming 96.71% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 35.09%, PTCT belongs to the top of the industry, outperforming 99.22% of the companies in the same industry.
Industry RankSector Rank
ROA 23.55%
ROE N/A
ROIC 35.09%
ROA(3y)-10.27%
ROA(5y)-18.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTCT Yearly ROA, ROE, ROICPTCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

1.3 Margins

  • With an excellent Profit Margin value of 39.44%, PTCT belongs to the best of the industry, outperforming 97.09% of the companies in the same industry.
  • The Operating Margin of PTCT (49.54%) is better than 99.61% of its industry peers.
  • The Gross Margin of PTCT (97.28%) is better than 96.71% of its industry peers.
  • PTCT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 49.54%
PM (TTM) 39.44%
GM 97.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.29%
GM growth 5Y0.47%
PTCT Yearly Profit, Operating, Gross MarginsPTCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PTCT Health Analysis

2.1 Basic Checks

  • PTCT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • PTCT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PTCT has more shares outstanding
  • Compared to 1 year ago, PTCT has an improved debt to assets ratio.
PTCT Yearly Shares OutstandingPTCT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
PTCT Yearly Total Debt VS Total AssetsPTCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • PTCT has an Altman-Z score of 1.86. This is not the best score and indicates that PTCT is in the grey zone with still only limited risk for bankruptcy at the moment.
  • PTCT has a Altman-Z score of 1.86. This is in the better half of the industry: PTCT outperforms 63.95% of its industry peers.
  • The Debt to FCF ratio of PTCT is 3.70, which is a good value as it means it would take PTCT, 3.70 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of PTCT (3.70) is better than 92.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.7
Altman-Z 1.86
ROIC/WACC4.6
WACC7.63%
PTCT Yearly LT Debt VS Equity VS FCFPTCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B

2.3 Liquidity

  • PTCT has a Current Ratio of 2.35. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
  • PTCT has a Current ratio of 2.35. This is in the lower half of the industry: PTCT underperforms 73.64% of its industry peers.
  • PTCT has a Quick Ratio of 2.27. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.27, PTCT is not doing good in the industry: 72.29% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 2.27
PTCT Yearly Current Assets VS Current LiabilitesPTCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PTCT Growth Analysis

3.1 Past

  • PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 228.79%, which is quite impressive.
  • Looking at the last year, PTCT shows a very strong growth in Revenue. The Revenue has grown by 114.51%.
  • The Revenue has been growing by 35.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)228.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.33%
Revenue 1Y (TTM)114.51%
Revenue growth 3Y35.3%
Revenue growth 5Y35.36%
Sales Q2Q%0.01%

3.2 Future

  • The Earnings Per Share is expected to decrease by -7.93% on average over the next years.
  • PTCT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.89% yearly.
EPS Next Y-110.07%
EPS Next 2Y-63.1%
EPS Next 3Y-21.39%
EPS Next 5Y-7.93%
Revenue Next Year-46.89%
Revenue Next 2Y-20.49%
Revenue Next 3Y-8.26%
Revenue Next 5Y-1.89%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PTCT Yearly Revenue VS EstimatesPTCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
PTCT Yearly EPS VS EstimatesPTCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

5

4. PTCT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.25, which indicates a very decent valuation of PTCT.
  • Based on the Price/Earnings ratio, PTCT is valued cheaper than 96.90% of the companies in the same industry.
  • PTCT is valuated cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
  • The Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 9.25
Fwd PE N/A
PTCT Price Earnings VS Forward Price EarningsPTCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PTCT is valued cheaply inside the industry as 97.67% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, PTCT is valued cheaper than 98.26% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.44
EV/EBITDA 6.45
PTCT Per share dataPTCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • PTCT's earnings are expected to decrease with -21.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.1%
EPS Next 3Y-21.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PTCT Dividend Analysis

5.1 Amount

  • No dividends for PTCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PTCT Fundamentals: All Metrics, Ratios and Statistics

PTC THERAPEUTICS INC

NASDAQ:PTCT (4/16/2026, 3:55:00 PM)

71.63

-1.94 (-2.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)04-23
Inst Owners113.34%
Inst Owner Change-0.05%
Ins Owners0.84%
Ins Owner Change6.88%
Market Cap5.93B
Revenue(TTM)1.73B
Net Income(TTM)682.64M
Analysts76.19
Price Target87.79 (22.56%)
Short Float %12.36%
Short Ratio8.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2175.84%
Min EPS beat(2)-4466.01%
Max EPS beat(2)114.33%
EPS beat(4)3
Avg EPS beat(4)103.66%
Min EPS beat(4)-4466.01%
Max EPS beat(4)4742.99%
EPS beat(8)5
Avg EPS beat(8)23.16%
EPS beat(12)5
Avg EPS beat(12)-13.42%
EPS beat(16)5
Avg EPS beat(16)-16.92%
Revenue beat(2)1
Avg Revenue beat(2)-6.39%
Min Revenue beat(2)-24.45%
Max Revenue beat(2)11.67%
Revenue beat(4)3
Avg Revenue beat(4)143.78%
Min Revenue beat(4)-24.45%
Max Revenue beat(4)585.33%
Revenue beat(8)5
Avg Revenue beat(8)74.62%
Revenue beat(12)7
Avg Revenue beat(12)49.28%
Revenue beat(16)9
Avg Revenue beat(16)36.95%
PT rev (1m)-1%
PT rev (3m)5.3%
EPS NQ rev (1m)1.95%
EPS NQ rev (3m)23.41%
EPS NY rev (1m)-19.07%
EPS NY rev (3m)15.68%
Revenue NQ rev (1m)-1.5%
Revenue NQ rev (3m)10.48%
Revenue NY rev (1m)-3.42%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE 9.25
Fwd PE N/A
P/S 3.43
P/FCF 8.44
P/OCF 8.34
P/B N/A
P/tB N/A
EV/EBITDA 6.45
EPS(TTM)7.74
EY10.81%
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)8.49
FCFY11.85%
OCF(TTM)8.59
OCFY12%
SpS20.91
BVpS-2.48
TBVpS-8.17
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 23.55%
ROE N/A
ROCE 44.41%
ROIC 35.09%
ROICexc N/A
ROICexgc N/A
OM 49.54%
PM (TTM) 39.44%
GM 97.28%
FCFM 40.58%
ROA(3y)-10.27%
ROA(5y)-18.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.29%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.7
Debt/EBITDA 2.26
Cap/Depr 22.83%
Cap/Sales 0.51%
Interest Coverage 150.35
Cash Conversion 79.36%
Profit Quality 102.89%
Current Ratio 2.35
Quick Ratio 2.27
Altman-Z 1.86
F-Score7
WACC7.63%
ROIC/WACC4.6
Cap/Depr(3y)14.48%
Cap/Depr(5y)22.46%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)228.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.33%
EPS Next Y-110.07%
EPS Next 2Y-63.1%
EPS Next 3Y-21.39%
EPS Next 5Y-7.93%
Revenue 1Y (TTM)114.51%
Revenue growth 3Y35.3%
Revenue growth 5Y35.36%
Sales Q2Q%0.01%
Revenue Next Year-46.89%
Revenue Next 2Y-20.49%
Revenue Next 3Y-8.26%
Revenue Next 5Y-1.89%
EBIT growth 1Y702.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-84.2%
EBIT Next 3Y-24.99%
EBIT Next 5YN/A
FCF growth 1Y715.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y760.42%
OCF growth 3YN/A
OCF growth 5YN/A

PTC THERAPEUTICS INC / PTCT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PTC THERAPEUTICS INC (PTCT) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PTCT.


What is the valuation status for PTCT stock?

ChartMill assigns a valuation rating of 5 / 10 to PTC THERAPEUTICS INC (PTCT). This can be considered as Fairly Valued.


What is the profitability of PTCT stock?

PTC THERAPEUTICS INC (PTCT) has a profitability rating of 5 / 10.


What is the financial health of PTC THERAPEUTICS INC (PTCT) stock?

The financial health rating of PTC THERAPEUTICS INC (PTCT) is 6 / 10.